MA41116A - Compositions d'inhibiteur de trans-signalisation par l'il-6 sélectif - Google Patents

Compositions d'inhibiteur de trans-signalisation par l'il-6 sélectif

Info

Publication number
MA41116A
MA41116A MA041116A MA41116A MA41116A MA 41116 A MA41116 A MA 41116A MA 041116 A MA041116 A MA 041116A MA 41116 A MA41116 A MA 41116A MA 41116 A MA41116 A MA 41116A
Authority
MA
Morocco
Prior art keywords
trans
selective
signaling inhibitor
inhibitor compositions
compositions
Prior art date
Application number
MA041116A
Other languages
English (en)
Other versions
MA41116B1 (fr
Inventor
Ian Cottingham
Jérémy Duboeuf
Daniel Plaksin
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of MA41116A publication Critical patent/MA41116A/fr
Publication of MA41116B1 publication Critical patent/MA41116B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5412—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
MA41116A 2014-12-01 2015-12-01 Compositions sélectives d'inhibiteur il-6-trans-signalisation MA41116B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14195726 2014-12-01
PCT/NL2015/050837 WO2016089206A2 (fr) 2014-12-01 2015-12-01 Compositions d'inhibiteur de trans-signalisation par l'il-6 sélectif
EP15834723.7A EP3227325B1 (fr) 2014-12-01 2015-12-01 Compositions sélectives d'inhibiteur il-6-trans-signalisation

Publications (2)

Publication Number Publication Date
MA41116A true MA41116A (fr) 2017-10-10
MA41116B1 MA41116B1 (fr) 2024-07-31

Family

ID=52000745

Family Applications (1)

Application Number Title Priority Date Filing Date
MA41116A MA41116B1 (fr) 2014-12-01 2015-12-01 Compositions sélectives d'inhibiteur il-6-trans-signalisation

Country Status (20)

Country Link
US (3) US10519218B2 (fr)
EP (2) EP4356962A3 (fr)
JP (2) JP6827941B2 (fr)
KR (2) KR20240131465A (fr)
CN (1) CN107406491A (fr)
CA (1) CA2969314A1 (fr)
DK (1) DK3227325T3 (fr)
ES (1) ES2981475T3 (fr)
FI (1) FI3227325T3 (fr)
HR (1) HRP20240581T1 (fr)
HU (1) HUE066987T2 (fr)
LT (1) LT3227325T (fr)
MA (1) MA41116B1 (fr)
MD (1) MD3227325T2 (fr)
MX (2) MX388268B (fr)
PL (1) PL3227325T3 (fr)
PT (1) PT3227325T (fr)
RS (1) RS65665B1 (fr)
SI (1) SI3227325T1 (fr)
WO (1) WO2016089206A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3226888B1 (fr) 2014-12-01 2021-04-21 Ferring B.V. Administration d'un inhibiteur de signalisation de trans-signalisation par il-6 sélectif
KR20240131465A (ko) * 2014-12-01 2024-08-30 훼링 비.브이. 선택적 il-6-트랜스-신호전달 억제제 조성물
WO2019086463A1 (fr) 2017-10-30 2019-05-09 Baxalta GmbH Détergents compatibles avec l'environnement pour l'inactivation de virus enveloppés de lipides
MX2020005630A (es) * 2017-11-30 2020-08-20 Bio Thera Solutions Ltd Formulacion liquida de anticuerpos humanizados para el tratamiento de enfermedades relacionadas con il-6.
JP7287611B2 (ja) * 2018-02-07 2023-06-06 学校法人日本医科大学 改良型アデノ随伴ウイルスベクター
MX2022015517A (es) * 2020-06-10 2023-01-16 Ferring Bv Compuesto farmaceutico para el tratamiento de la enfermedad cardiovascular aterosclerotica.
WO2022139580A1 (fr) 2020-12-22 2022-06-30 Ferring B.V. Biomarqueurs d'expression de gènes sanguins pour prédire une réponse chez des patients atteints de maladies intestinales inflammatoires
CN114681592A (zh) * 2020-12-31 2022-07-01 天境生物科技(杭州)有限公司 包含可溶性gp130二聚体的制剂和使用方法
WO2024011946A1 (fr) * 2022-07-12 2024-01-18 I-Mab Biopharma (Hangzhou) Co., Ltd Dimères polypeptidiques pour le traitement de la sclérose systémique

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
JPH04218000A (ja) 1990-02-13 1992-08-07 Kirin Amgen Inc 修飾ポリペプチド
WO1994012520A1 (fr) 1992-11-20 1994-06-09 Enzon, Inc. Segment de liaison pour polypeptides fusionnes lies
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
US5783672A (en) 1994-05-26 1998-07-21 Immunex Corporation Receptor for oncostatin M
US6472179B2 (en) * 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
DE19941897B4 (de) 1999-09-02 2006-06-14 GSF - Forschungszentrum für Umwelt und Gesundheit GmbH IL-6 Rezeptor-Protein, Beta-Kette (gp130) des IL-6 Rezeptor-Proteins, für diese Proteine kodierende DNA, davon abgeleitete RNA, Peptid mit den Aminosäuren 771-811 dieser Beta-Kette oder Teilen davon und deren Verwendungen
JP5179689B2 (ja) 2000-02-11 2013-04-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗体ベース融合タンパク質の循環系内半減期の増強
DE60037648T2 (de) 2000-04-21 2010-06-17 Conaris Research Institute Ag Fusionsproteine, die zwei lösliche gp130 Moleküle enthalten
KR20030097876A (ko) 2001-05-21 2003-12-31 넥타르 테라퓨틱스 화학적으로 개질된 인슐린의 폐 투여
WO2003008454A2 (fr) 2001-07-18 2003-01-30 Merck Patent Gmbh Proteine de fusion, glycoproteine vi
WO2003024389A2 (fr) 2001-07-30 2003-03-27 Immunex Corporation Imx97018, polypeptide humain de type ataxine-1
JP2004182638A (ja) 2002-12-03 2004-07-02 Yakult Honsha Co Ltd 炎症性疾患又は悪性腫瘍の予防治療剤
EP1491554A1 (fr) 2003-06-23 2004-12-29 CONARIS research institute AG Solubles gp130-dimeres modifiée avec du PEG pour utilisation comme medicament
ES2309427T3 (es) 2004-08-27 2008-12-16 Conaris Research Institute Ag Secuencias de nucleotidos optimizidas que codifican para sgp130.
EP1801121A1 (fr) 2005-12-23 2007-06-27 CONARIS research institute AG Variantes solubles de la molécule gp130 utiles comme médicament
CN101346395A (zh) * 2005-12-30 2009-01-14 默克专利有限公司 阻止复合有IL-6Rα的IL-6与GP130结合的抗IL-6抗体
DE602006016765D1 (de) * 2006-06-30 2010-10-21 Conaris Res Inst Ag Verbesserte sgp 130Fc Dimere
KR20140107702A (ko) * 2006-06-30 2014-09-04 코나리스 리써치 인스티튜트 아게 개선된 ｓｇｐ130Ｆｃ 이량체
EP2050759A1 (fr) 2007-10-19 2009-04-22 CONARIS research institute AG Mutéines gp 130 solubles dotées d'une activité de liaison améliorée
MX2013006234A (es) 2011-01-06 2013-08-01 Univ Johns Hopkins Metodo para la produccion de glicoproteinas recombinantes con semivida en circulacion incrementada en celulas de mamifero.
KR20240131465A (ko) 2014-12-01 2024-08-30 훼링 비.브이. 선택적 il-6-트랜스-신호전달 억제제 조성물
EP3226888B1 (fr) * 2014-12-01 2021-04-21 Ferring B.V. Administration d'un inhibiteur de signalisation de trans-signalisation par il-6 sélectif

Also Published As

Publication number Publication date
PT3227325T (pt) 2024-07-01
MA41116B1 (fr) 2024-07-31
SI3227325T1 (sl) 2024-06-28
EP3227325B1 (fr) 2024-04-10
ES2981475T3 (es) 2024-10-09
EP4356962A3 (fr) 2024-07-24
US10519218B2 (en) 2019-12-31
FI3227325T3 (fi) 2024-07-10
US20220275056A1 (en) 2022-09-01
CA2969314A1 (fr) 2016-06-09
KR20240131465A (ko) 2024-08-30
EP3227325A2 (fr) 2017-10-11
PL3227325T3 (pl) 2024-10-07
LT3227325T (lt) 2024-05-27
JP6827941B2 (ja) 2021-02-10
MX388268B (es) 2025-03-18
HUE066987T2 (hu) 2024-09-28
KR102699098B1 (ko) 2024-08-27
WO2016089206A3 (fr) 2016-07-28
MX2017007069A (es) 2018-02-09
US20200123226A1 (en) 2020-04-23
CN107406491A (zh) 2017-11-28
MX2021007899A (es) 2021-09-08
JP2021073229A (ja) 2021-05-13
RS65665B1 (sr) 2024-07-31
JP7184936B2 (ja) 2022-12-06
MD3227325T2 (ro) 2024-09-30
US20180282396A1 (en) 2018-10-04
KR20170135818A (ko) 2017-12-08
EP4356962A2 (fr) 2024-04-24
WO2016089206A2 (fr) 2016-06-09
HRP20240581T1 (hr) 2024-07-19
US11306136B2 (en) 2022-04-19
JP2017536848A (ja) 2017-12-14
DK3227325T3 (da) 2024-07-08

Similar Documents

Publication Publication Date Title
FIC20240013I1 (fi) Lebrikitsumabi
EP3534968A4 (fr) Compositions de lymphocytes t car anti-bcma
DK3497103T3 (da) Pyridopyrimdinon-cdk2/4/6-inhibitorer
EP3541932A4 (fr) Inhibiteurs de crispr-cas9
PL3151672T3 (pl) Ulepszone kompozycje limfocytów t
DK3361870T3 (da) Fungicidsammensætninger
EP3334403A4 (fr) Compositions topiques
LT3240416T (lt) Fungicidinės kompozicijos
CU20160125A7 (es) Inhibidores de diacilglicerol aciltransferasa 2
DK3416996T3 (da) Hærdelig sammensætning
DK3542812T3 (da) Glycopeptidsammensætninger
EP3313828A4 (fr) Inhibiteurs de métallo-bêta-lactamases
BR112017001922A2 (pt) composições fungicidas
DK3250182T3 (da) Dispergible sammensætninger
DK3334726T3 (da) Plinabulinsammensætninger
DK3116475T3 (da) Dopa-decarboxylasehæmmersammensætninger
DK3240767T3 (da) Mikroindkapslede nitrifikationshæmmersammensætninger
EP3397239A4 (fr) Compositions topiques
MA43367A (fr) Inhibiteurs de métallo-bêta-lactamases
PL3227325T3 (pl) Selektywne kompozycje inhibitorów trans-sygnałowania il-6
DK4234656T3 (da) Sammensætninger
DK3137437T3 (da) Mikroindkapslet nitrifikationsinhibitorsammensætning
PL3226888T3 (pl) Podawanie selektywnego transsygnałowego inhibitora IL-6
DK3316857T3 (da) Multifasiske sammensætninger
DK3317458T3 (da) Mineralsammensætninger